• Adina-Elena Nenciu Bucharest University Emergency Hospital, Bucharest, Romania
  • C. G. Nenciu “St. John” Emergency Hospital, Bucur Maternity Bucharest, Romania
  • R. Fodoroiu Bucharest University Emergency Hospital, Bucharest, Romania
  • Florica Șandru “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania; “Elias” Emergency Hospital, Bucharest, Romania
  • M.C. Dumitrașcu Bucharest University Emergency Hospital, Bucharest, Romania; “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
Keywords: tumor markers, ovarian cancer, diagnosis, prognosis


Even if today’s society is rapidly evolving there is still much that can be done. This applies in the
oncological field. One of the main female health problems worldwide is represented by the
gynecological cancers. Ovarian cancer is the main cause of mortality among women with
gynecological cancers. Although its prevalence is lover compared to breast, uterine or cervical
cancer, the mortality and morbidity rates are significantly higher. The first step in the management
of ovarian cancer is represented by regular screening and rapid diagnosis. One of the most important
tolls is represented by serological markers dosage in order to estimate the type of tumor before the
gynecological specific intervention. There is a real need to identify correctly the ovarian cancer as
early as possible in order to obtain the favorable prognosis that comes with the diagnosis in earlystage. Most of the ovarian cancers (above 90%) are represented by carcinomas which are frequently
diagnosed in advanced stages. The roles of the biomarkers are to indicate the malignancy of an
ovarian tumor and to predict the relapse risk. The aim of this paper is to update the indications
regarding the usage of serological markers in ovarian cancers and the importance of using them for
our patients.


[1] Momenimovahed Z, Tiznobaik A, Taheri S,
Salehiniya H. Ovarian cancer in the world:
epidemiology and risk factors. Int J Womens Health.
2019;11:287–299. Published 2019 Apr 30.
[2] Coburn SB, Bray F, Sherman ME, Trabert B.
International patterns and trends in ovarian cancer
incidence, overall and by histologic subtype. Int J
Cancer. 2017 Jun 1; 140(11):2451-2460.
[3] Yoneda A, Lendorf ME, Couchman JR,
Multhaupt HA Breast and ovarian cancers: a survey
and possible roles for the cell surface heparan sulfate
proteoglycans. J Histochem Cytochem. 2012 Jan;
[4] Sopik V, Iqbal J, Rosen B, Narod SA Why have
ovarian cancer mortality rates declined? Part I.
Incidence. Gynecol Oncol. 2015 Sep; 138(3):741-9.
[5] Isherwood A, Bamford J, Dupuy AV. Ovarian
cancer in select EU countries: incidence, treatable
populations and sales by key drug class. Rev
Epidemiol Sante Publique. 2018;66:S286.
[6] Bray F, Ferlay J, Soerjomataram I, Siegel RL,
Torre LA, Jemal A. Global cancer statistics 2018:
GLOBOCAN estimates of incidence and mortality
worldwide for 36 cancers in 185 countries. CA
Cancer J Clin. 2018 Nov; 68(6):394-424.
[7] Andrews L, Mutch DG. Hereditary Ovarian
Cancer and Risk Reduction. Best Pract Res Clin
Obstet Gynaecol. 2017 May; 41():31-48.
[8] Ørskov M, Iachina M, Guldberg R, Mogensen O,
Mertz Nørgård B. Predictors of mortality within 1
year after primary ovarian cancer surgery: a
nationwide cohort study. BMJ Open. 2016 Apr 21;
[9] Prat, Jaime, and FIGO Committee on Gynecologic
Oncology. “FIGO's staging classification for cancer
of the ovary, fallopian tube, and peritoneum: abridged
republication.” Journal of gynecologic oncology vol.
26,2 (2015): 87-9. doi:10.3802/jgo.2015.26.2.87.
[10] Karen Eagle Jonathan A. Ledermann Tumor
Markers in Ovarian Malignancies. The Oncologist.
01 October 1997
[11] Malati Tangirala, G. Rajani Kumari, B Yadagiri.
Application of tumor markers in ovarian
malignancies. Indian Journal of Clinical
Biochemistry 16(2):224-33 · July 2001.
[12] Meinhold-Heerlein I, Fotopoulou C, Harter P,
Kurzeder C, Mustea A, Wimberger P, Hauptmann S,
Sehouli J. The new WHO classification of ovarian,
fallopian tube, and primary peritoneal cancer and its
clinical implications. Arch Gynecol Obstet. 2016
Apr;293(4):695-700. doi: 10.1007/s00404-016-4035-
8. Epub 2016 Feb 19.
[13] Dochez V, Caillon H, Vaucel E, Dimet J, Winer
N, Ducarme G. Biomarkers and algorithms for
diagnosis of ovarian cancer: CA125, HE4, RMI and
ROMA, a review. J Ovarian Res. 2019;12(1):28.
Published 2019 Mar 27. doi:10.1186/s13048-019-
[14] Bast RC Jr, Feeney M, Lazarus H, Nadler LM,
Colvin RB, Knapp RC. Reactivity of a monoclonal
antibody with human ovarian carcinoma. J Clin
Invest. 1981 Nov; 68(5):1331-7.
[15] Enakpene CA, Omigbodun AO, Goecke TW,
Odukogbe AT, Beckmann MW. Preoperative
evaluation and triage of women with suspicious
adnexal masses using risk of malignancy index. J
Obstet Gynaecol Res. 2009 Feb; 35(1):131-8.
[16] Clarke-Pearson, D. L. (2009). Clinical practice.
Screening for ovarian cancer. N. Engl. J. Med. 361,
170–177. doi: 10.1056/NEJMcp0901926.
[17] Wei-Lei Yang, Zhen Lu, and Robert C. Bast Jr.
The Role of Biomarkers in the Management of
Epithelial Ovarian Cancer. Expert Rev Mol Diagn.
2017 June ; 17(6): 577–591.
[18] Rustin GJ, van der Burg ME, Griffin CL, et al.
Early versus delayed treatment of relapsed ovarian
cancer (MRC OV05/EORTC 55955): a randomised
trial. Lancet. 2010; 376(9747):1155–1163.
[19] van Nagell JR Jr, DePriest PD, Ueland FR, et al.
Ovarian cancer screening with annual transvaginal
sonography: findings of 25,000 women screened.
Cancer. 2007; 109(9):1887–1896.
[20] Welsh JB, Zarrinkar PP, Sapinoso LM, et al.
Analysis of gene expression profiles in normal and
neoplastic ovarian tissue samples identifies candidate
molecular markers of epithelial ovarian cancer. Proc
Natl Acad Sci U S A. 2001; 98(3):1176–1181.
[21] Kirchhoff C, Habben I, Ivell R, Krull N. A major
human epididymis-specific cDNA encodes a protein
with sequence homology to extracellular proteinase
inhibitors. Biol Reprod. 1991 Aug; 45(2):350-7.
[22] Simmons, Archana R et al. “The emerging role
of HE4 in the evaluation of epithelial ovarian and
Journal of Surgical Sciences Vol.7, No.2, April – June 2020
endometrial carcinomas.” Oncology (Williston Park,
N.Y.) vol. 27,6 (2013): 548-56.
[23] Lu R, Sun X, Xiao R, Zhou L, Gao X, Guo L.
Human epididymis protein 4 (HE4) plays a key role
in ovarian cancer cell adhesion and motility. Biochem
Biophys Res Commun. 2012 Mar 9; 419(2):274-80.
[24] Iwahori K, Suzuki H, Kishi Y, Fujii Y, Uehara
R, Okamoto N, Kobayashi M, Hirashima T, Kawase
I, Naka T. Serum HE4 as a diagnostic and prognostic
marker for lung cancer. Tumour Biol. 2012 Aug;
[25] Nagy B Jr, Krasznai ZT, Balla H, Csobán M,
Antal-Szalmás P, Hernádi Z, Kappelmayer J.
Elevated human epididymis protein 4 concentrations
in chronic kidney disease. Ann Clin Biochem. 2012
Jul; 49(Pt 4):377-80.
[26] Xiang W, Lv Q, Shi H, Xie B, Gao L. Aptamerbased biosensor for detecting carcinoembryonic
antigen. Talanta. 2020 Jul 1;214:120716. doi:
10.1016/j.talanta.2020.120716. Epub 2020 Jan 11.
[27] Guo, J., Yu, J., Song, X., & Mi, H. (2017). Serum
CA125, CA199 and CEA Combined Detection for
Epithelial Ovarian Cancer Diagnosis: A Metaanalysis. Open medicine (Warsaw, Poland), 12, 131–
137. https://doi.org/10.1515/med-2017-0020.
[28] Moro F, Pasciuto T, Djokovic D, Di Legge A,
Granato V, Moruzzi MC, Mancari R, Zannoni GF,
Fischerova D, Franchi D, Scambia G, Testa AC. Role
of CA125/CEA ratio and ultrasound parameters in
identifying metastases to the ovaries in patients with
multilocular and multilocular-solid ovarian masses.
Ultrasound Obstet Gynecol. 2019 Jan;53(1):116-123.
doi: 10.1002/uog.19174.
[29] Kiluk MS1, Rółkowski R, Zawadzki RJ,
Wojtukiewicz MZ. Usefulness of CEA, CA 15-3 and
CA 125 tumor markers in the differential diagnostics
of peritoneal effusion. Pol Merkur Lekarski. 2002
[30] Sofie Sølvsten Sørensen & Berit Jul Mosgaard.
Combination of cancer antigen 125 and
carcinoembryonic antigen can improve ovarian
cancer diagnosis. Dan Med Bul 58/11 November
[31] I Cooke, M O'Brien, FM Charnock, N Groome
and T S Ganesan. Inhibin as a marker for ovarian
cancer. BUsh Jojam d Cmc (1 ) 71, 1046-1050f ©
1995 tocddon Press Al rhts reseved 0007-0920/95.
[32] Healy DL, Burger HG, Mamers P et al.: Elevated
serum inhibin concentrations in postmenopausal
women with ovarian tumours. N. Engl. J. Med. 329,
1539–1542 (1993).
[33] David M Robertson & Martin K Oehler.
Emerging role of inhibin as a biomarker for ovarian
cancer. Future Medicine Ltd ISSN 1745-5057
Women's Health (2005) 1(1), 51-57.
[34] Singh, P., Jenkins, L. M., Horst, B., Alers, V.,
Pradhan, S., Kaur, P., Srivastava, T., Hempel, N.,
Győrffy, B., Broude, E. V., Lee, N. Y., & Mythreye,
K. (2018). Inhibin Is a Novel Paracrine Factor for
Tumor Angiogenesis and Metastasis. Cancer
research, 78(11), 2978–2989.
[35] Walentowicz, P., Krintus, M., Sadlecki, P.,
Grabiec, M., Mankowska-Cyl, A., Sokup, A., &
Walentowicz-Sadlecka, M. (2014). Serum inhibin A
and inhibin B levels in epithelial ovarian cancer
patients. PloS one, 9(3), e90575.
[36] Jiangdong Xiang Lina Zhou Yan Zhuang Jin
Zhang Ya Sun Shuangdi Li Zhenbo Zhang Gao
Zhang Yinyan He. Lactate dehydrogenase is
correlated with clinical stage and grade and is
downregulated by si‑SAΤB1 in ovarian cancer.
ONCOLOGY REPORTS 4 2788 0: 2788-2797, 2018.
DOI: 10.3892/or.2018.6658.
[37] Schneider D, Halperin R, Langer R, Bukovsky I,
Herman A. Peritoneal fluid lactate dehydrogenase in
ovarian cancer. Gynecol Oncol. 1997 Sep;66(3):399-
[38] Xiang J, Zhou L, Zhuang Y, Zhang J, Sun Y, Li
S, Zhang Z, Zhang G, He Y. Lactate dehydrogenase
is correlated with clinical stage and grade and is
downregulated by si‑SAΤB1 in ovarian cancer. Oncol
Rep. 2018 Nov;40(5):2788-2797. doi:
10.3892/or.2018.6658. Epub 2018 Aug 17.
How to Cite
A.-E. Nenciu, C. Nenciu, R. Fodoroiu, F. Șandru, and M. Dumitrașcu, “TUMOR MARKERS IN OVARIAN CANCER”, JSS, vol. 7, no. 2, pp. 79-84, Sep. 2020.